Oxford Biomedica (OXB)

Sector:

Pharma and Biotech

Index:

FTSE 250

762.00p
   
  • Change Today:
    -14.00p
  • 52 Week High: 853.00
  • 52 Week Low: 400.00
  • Currency: UK Pounds
  • Shares Issued: 82.05m
  • Volume: 48,995
  • Market Cap: £625.20m
  • RiskGrade: 289

Oxford Biomedica joins Covid-19 vaccine consortium

By Josh White

Date: Wednesday 08 Apr 2020

LONDON (ShareCast) - (Sharecast News) - Gene and cell therapy company Oxford Biomedica has joined a consortium led by the Jenner Institute at Oxford University, it announced on Wednesday, to rapidly develop, scale-up and manufacture a potential vaccine candidate for Covid-19, called 'ChAdOx1 nCov-19'.
The London-listed firm said the vaccine candidate was "one of the leading" vaccine candidates currently in development globally, and was expected to be the UK's first Covid-19 vaccine in clinical trials later in April.

It said the consortium was led by the Jenner Institute at the University of Oxford, and also included the Vaccines Manufacturing and Innovation Centre (VMIC), Pall Life Sciences, Cobra Biologics and Halix BV.

The Jenner Institute and the Oxford Vaccine Group had already recruited individuals aged between 18 and 55 from the Thames Valley area, to study the vaccine's safety and efficacy.

Oxford Biomedica said it would provide access to its large scale GMP manufacturing facilities for viral vectors, including its new Oxbox facility, to the consortium as required, which - along with other consortium manufacturing partners in the UK and internationally - would allow for scaled manufacturing capacity should the safety and efficacy of the vaccine candidate be confirmed in clinical trials.

The Oxford vaccine candidate relied on adenoviral vector technology, 'ChAdOx1', developed at the Jenner Institute in Oxford.

It was seen as "one of the most promising" vaccine technologies for Covid-19, Ocford Biomedica claimed, as ChAdOx1 had been shown to generate a strong immune response from one dose, and had demonstrated a good safety profile in pre-clinical and clinical trials conducted to date.

No financial terms were disclosed in the announcement.

"As an established clinical and commercial manufacturer of viral vectors, we are very pleased to be in a strong position in terms of capacity and capabilities to support the important and urgent efforts of the consortium led by the Jenner Institute, University of Oxford, to develop and scale up manufacturing of this promising vaccine candidate for Covid-19," said chief executive officer John Dawson.

"While our current activities on this vaccine candidate are just initiating, should the consortium confirm there is promise for this candidate in the clinical trial initiating this month, we will play our role within the consortium to scale up manufacturing as fast as possible.

"This will help to provide significant access to the vaccine candidate for further clinical trials and potentially, if approved for use, for many people in the UK and beyond."

At 1611 BST, shares in Oxford Biomedica were up 22.68% at 687p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

OXB Market Data

Currency UK Pounds
Share Price 762.00p
Change Today -14.00p
% Change -1.80 %
52 Week High 853.00
52 Week Low 400.00
Volume 48,995
Shares Issued 82.05m
Market Cap £625.20m
RiskGrade 289

OXB Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
31.01% below the market average31.01% below the market average31.01% below the market average31.01% below the market average31.01% below the market average
7.14% above the sector average7.14% above the sector average7.14% above the sector average7.14% above the sector average7.14% above the sector average
Price Trend
57.55% above the market average57.55% above the market average57.55% above the market average57.55% above the market average57.55% above the market average
22.81% above the sector average22.81% above the sector average22.81% above the sector average22.81% above the sector average22.81% above the sector average
Income Not Available
Growth
16.27% above the market average16.27% above the market average16.27% above the market average16.27% above the market average16.27% above the market average
8.57% below the sector average8.57% below the sector average8.57% below the sector average8.57% below the sector average8.57% below the sector average

What The Brokers Say

Strong Buy 4
Buy 0
Neutral 1
Sell 0
Strong Sell 0
Total 5
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

OXB Dividends

No dividends found

Trades for 07-Jul-2020

Time Volume / Share Price
15:49 454 @ 762.80p
15:26 263 @ 762.00p
15:18 431 @ 763.48p
15:10 3 @ 765.95p
15:05 2 @ 763.46p

OXB Key Personnel

CEO John Dawson
CFO Stuart Paynter

Top of Page